Zealand Pharma stock plunges on safety data concerns

Zealand Pharma's trading volume will remain elevated (average daily volume increase of at least 40%) for 45 days following the safety data announcement, indicating sustained investor uncertainty and reallocation activity

Zealand Pharma's clinical trial enrollment for the weight loss drug program will decline by more than 20% in the 90 days following the safety data disclosure, as measured by regulatory filings or company guidance updates

Zealand Pharma (ZEAL) stock will experience a recovery of at least 15% within 60 days following negative safety data release, driven by institutional buying at depressed valuations and positive analyst reassessments